← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Meissa Vaccines, Inc.
South San Francisco, CA
$2,369,925
Total funding
4
Grants
Funding over time
peak $1.4M · FY2017–19$2M$1.5M$1M$500K$0
'17
'18
'19
Funding mix
By agency
NIH$2,369,925 · 4
By mechanism
R44$1,563,412 · 1
R56$369,625 · 1
R34$220,500 · 1
R43$216,388 · 1
Investigators at Meissa Vaccines, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Development of live attenuated respiratory syncytial virus vaccines with novel thermal stable fusion protein$999,722
R44 · FY2018 · AI
Rationally designed live attenuated RSV vaccines$369,625
R56 · FY2018 · AI
Development of live attenuated respiratory syncytial virus vaccines with novel thermal stable fusion protein$339,597
R44 · FY2019 · AI
Development of live attenuated respiratory syncytial virus vaccines with novel thermal stable fusion protein$224,093
R44 · FY2017 · AI
A Phase 1 Study to Evaluate the Safety and Immunogenicity of a Novel Live Attenuated Respiratory Syncytial Virus Vaccine with Thermal Stable Fusion protein in Seropositive Adults and Children$220,500
R34 · FY2019 · AI
Development of polyvalent inactivated rhinovirus vaccine$216,388
R43 · FY2017 · AI